Share
CyberKnife, SBRT and proton therapy are often compared as though they were three competing versions of the same treatment. They are not. One is a delivery platform, one is a technique and one uses a different type of radiation particle.
For a patient, the most useful question is not “Which sounds most advanced?” It is: “Which treatment can cover this tumour effectively while keeping the risk to nearby healthy tissues acceptable?” The answer depends on the cancer, anatomy, previous treatment and the actual plan.
The names describe different things
If the table extends beyond your screen, swipe or scroll sideways to read every column.
Term | What it means | What to remember |
|---|---|---|
SBRT | Stereotactic body radiotherapy: highly focused radiation to a defined target outside the brain, usually in a limited number of sessions | It is a technique that can be delivered using different machines. |
SRS | Stereotactic radiosurgery, most commonly used for brain targets | Despite “surgery” in the name, it is radiation treatment, not an incision. |
CyberKnife | A robotic image-guided radiation-delivery system | It can deliver stereotactic treatments; it is not a separate biological therapy. |
Proton therapy | Radiation using protons rather than photons | Its dose distribution can help spare some normal tissues in selected situations. |
Conventional modern radiotherapy also includes techniques such as IMRT and image-guided treatment. A carefully planned course on an appropriate standard platform can be excellent care; a machine name alone cannot establish a better outcome.
What is SBRT trying to achieve?
SBRT delivers a concentrated dose to a well-defined target with careful positioning and image guidance. It may be considered for selected primary cancers or limited metastatic sites. Suitability depends on size, location, movement, nearby organs and the overall disease situation.
A limited number of sessions can be convenient, but convenience is not the only aim. Larger doses per session may be inappropriate when sensitive tissues cannot be sufficiently protected. More fractions can sometimes be the safer choice.
Focused treatment controls the treated area. It does not automatically treat microscopic disease elsewhere, so systemic therapy or other care may still be needed.
What does CyberKnife add?
CyberKnife is one platform for delivering precise radiation with robotic positioning and image guidance. Depending on the target and technique, it can track or account for movement during treatment. It may be used for stereotactic treatment in selected brain and body sites.
Despite the name, no knife removes the tumour. Some patients may nevertheless need a separate preparatory procedure, such as placement of markers, depending on the treatment plan. Non-invasive delivery does not mean there are no side effects or no preparation.
Ask why this platform is preferable for your target, whether another suitable machine could deliver the planned treatment and whether any difference is clinically meaningful rather than simply technical.
How is proton therapy different?
Protons deposit energy differently from photons. The treatment can be designed to reduce radiation beyond a target, which may help spare normal tissues in selected circumstances. This can be particularly relevant for some childhood cancers, complex anatomy or situations where dose to vulnerable structures is a major concern.
It does not mean zero exposure to healthy tissue, zero side effects or better cancer control in every disease. Motion, anatomy, uncertainty and the quality of the plan still matter.
Ask what advantage the team expects for you: reduced dose to a particular organ, fewer significant side effects or a better ability to deliver the required dose. A theoretical planning advantage and a proven improvement in long-term clinical outcomes are not identical.
Why the treatment plan matters more than the label
The radiation oncologist considers what needs treating, its relationship to normal organs and how much dose those tissues can tolerate. Physicists and radiation therapists contribute to planning, checking and accurate delivery.
For a moving lung or abdominal target, motion management may be important. A tumour close to the spinal cord requires attention to dose constraints. If a large region or multiple areas need treatment, a highly focal approach alone may not cover the clinical problem.
A comparison should therefore consider target coverage, normal-tissue doses, likely side effects, treatment burden and evidence—not just whether one machine is newer.
Is stereotactic treatment an alternative to surgery?
Sometimes it is an option, but the answer is disease-specific. Operability, tumour biology, the need for tissue information, lymph-node assessment and expected outcomes all affect the comparison.
For some patients an operation is preferred; others may benefit from radiation when surgery is unsuitable or carries significant risk. In still other situations medicines are central and a local treatment has a supporting role.
This is a useful setting for multidisciplinary review. Ask whether the relevant surgeon, medical oncologist and radiation oncologist have considered the sequence together.
What about metastatic cancer?
Radiation may relieve symptoms, protect a threatened structure or treat selected metastatic sites. Some patients with limited disease may be considered for a more intensive local-treatment strategy, but treating every visible spot is not automatically a cure.
The original cancer, number and distribution of lesions, response to systemic treatment and likelihood of further spread influence the decision. Ask what treating a particular site is expected to change for the whole patient.
A high local-control rate for the treated lesion is not the same as a cure rate for metastatic cancer. Both facts matter, but they answer different questions.
Can radiation be given again to the same area?
Sometimes, but re-irradiation requires careful assessment of previous dose, overlap, elapsed time, current anatomy and expected benefit. Prior treatment records and preferably the actual radiation plan are important. A newer machine does not erase the dose healthy tissues have already received.
Ask whether the team has the previous plan and what risks make the new treatment acceptable or unacceptable. Stereotactic or proton techniques may help in selected cases but are not automatic solutions to every previously treated area.
What happens before and during treatment?
Planning often starts with a simulation scan and a reproducible position. A mask, body support or another device may keep the target aligned. Further imaging or breathing-control methods may be required. The team then designs and checks the treatment before delivery.
Treatment sessions involve careful setup as well as radiation time. Ask about appointment duration, transport, medicines and whether you need someone to accompany you. External-beam radiotherapy generally does not make you radioactive afterwards; different precautions may apply to internal or radionuclide treatments.
Side effects depend on the area treated, dose and schedule. Fatigue, local inflammation or organ-specific symptoms may occur, and some effects develop later. A short course is not synonymous with a risk-free course.
What should I ask before choosing a centre?
Ask which technique is recommended and why, what alternatives exist, how many sessions are expected and which meaningful side effects the plan aims to reduce. Request the anticipated cost of the complete pathway, including planning and additional procedures.
Clarify coordination with chemotherapy, immunotherapy or surgery and whether treatment can be delivered nearer home without compromising the plan. Travel and accommodation are relevant, particularly for a prolonged course.
Do not pay for a technology solely because it is described as the most advanced. Ask what additional benefit justifies it in your specific situation.
Access through the Apollo network
Apollo Cancer Centre Bengaluru offers the CyberKnife S7 system. Patients whose plans may benefit from proton therapy can be evaluated through Apollo Proton Cancer Centre in Chennai. CTI’s oncology team can coordinate with the relevant radiation specialists; assessment determines suitability and location. These facilities are not all at every Bengaluru centre.
Frequently asked questions
Is CyberKnife surgery?
No. It delivers radiation. Some preparation may involve a separate procedure, but the radiation itself does not involve cutting out the tumour.
Does proton therapy always have fewer side effects?
No. It may reduce normal-tissue dose in selected situations, but the benefit depends on the target and plan. Ask which specific risk is expected to be reduced.
Can fewer sessions mean stronger treatment?
A schedule reflects dose, biology and safety. Fewer fractions do not automatically mean more effective care; some cancers need a longer course.
Can I choose the machine myself?
You can discuss preferences, costs and travel, but the decision should follow specialist planning. The aim is an appropriate treatment, not a brand selection.
The right radiation treatment is the one that solves the clinical problem safely—not the one with the most impressive name.
Medical information notice: This information is for general education and does not replace individual medical advice. Cancer treatment depends on the diagnosis, stage, tumour biology, previous treatment, general health and individual circumstances.
